Comparison 3. PLD + other drug vs PLD.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 PFS	3		Hazard Ratio (Random, 95% CI)	Subtotals only
1.1 TBD/PLD vs PLD	1	672	Hazard Ratio (Random, 95% CI)	0.79 [0.65, 0.96]
1.2 CAN/PLD vs PLD	1	125	Hazard Ratio (Random, 95% CI)	0.92 [0.58, 1.46]
1.3 EC145/PLD vs PLD	1	149	Hazard Ratio (Random, 95% CI)	0.63 [0.41, 0.97]
2 PFS: PPS subgroup only	1		Hazard Ratio (Random, 95% CI)	Subtotals only
2.1 PLD/TBD vs PLD	1	208	Hazard Ratio (Random, 95% CI)	0.65 [0.45, 0.93]
3 OS	3		Hazard Ratio (Random, 95% CI)	Subtotals only
3.1 TBD/PLD vs PLD	1		Hazard Ratio (Random, 95% CI)	0.86 [0.72, 1.02]
3.2 CAN/PLD vs PLD	1		Hazard Ratio (Random, 95% CI)	0.0 [0.0, 0.0]
3.3 EC145/PLD vs PLD	1		Hazard Ratio (Random, 95% CI)	1.01 [0.68, 1.50]
4 SAE: Anaemia (G3/4)	3		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
4.1 TBD/PLD vs PLD	1	663	Risk Ratio (M‐H, Random, 95% CI)	2.54 [1.45, 4.43]
4.2 CAN/PLD vs PLD	1	122	Risk Ratio (M‐H, Random, 95% CI)	1.93 [0.71, 5.22]
4.3 EC145/PLD vs PLD	1	157	Risk Ratio (M‐H, Random, 95% CI)	0.53 [0.22, 1.28]
5 SAE: Neutropenia (G3/4)	3		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
5.1 TBD/PLD vs PLD	1	663	Risk Ratio (M‐H, Random, 95% CI)	2.80 [2.25, 3.48]
5.2 CAN/PLD vs PLD	1	122	Risk Ratio (M‐H, Random, 95% CI)	2.19 [1.05, 4.59]
5.3 EC145/PLD vs PLD	1	157	Risk Ratio (M‐H, Random, 95% CI)	1.07 [0.55, 2.08]
6 SAE: Thrombocytopenia (G3/4)	3		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
6.1 TBD/PLD vs PLD	1	663	Risk Ratio (M‐H, Random, 95% CI)	7.56 [3.67, 15.54]
6.2 CAN/PLD vs PLD	1	122	Risk Ratio (M‐H, Random, 95% CI)	8.77 [1.16, 66.41]
6.3 EC145/PLD vs PLD	1	157	Risk Ratio (M‐H, Random, 95% CI)	0.47 [0.12, 1.79]
7 SAE: Vomiting (G3/4)	3		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
7.1 TBD/PLD vs PLD	1	663	Risk Ratio (M‐H, Random, 95% CI)	4.81 [2.16, 10.70]
7.2 CAN/PLD vs PLD	1	122	Risk Ratio (M‐H, Random, 95% CI)	1.46 [0.37, 5.85]
7.3 EC145/PLD vs PLD	1	157	Risk Ratio (M‐H, Random, 95% CI)	0.06 [0.01, 0.45]
8 SAE: HFS (G3)	3		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
8.1 TBD/PLD vs PLD	1	663	Risk Ratio (M‐H, Random, 95% CI)	0.20 [0.11, 0.35]
8.2 CAN/PLD vs PLD	1	122	Risk Ratio (M‐H, Random, 95% CI)	0.50 [0.15, 1.62]
8.3 EC145/PLD vs PLD	1	157	Risk Ratio (M‐H, Random, 95% CI)	2.57 [0.59, 11.16]
9 SAE: Stomatitis (G3/4)	3		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
9.1 TBD/PLD vs PLD	1	663	Risk Ratio (M‐H, Random, 95% CI)	0.17 [0.05, 0.59]
9.2 CAN/PLD vs PLD	1	122	Risk Ratio (M‐H, Random, 95% CI)	0.70 [0.20, 2.49]
9.3 EC145/PLD vs PLD	1	157	Risk Ratio (M‐H, Random, 95% CI)	0.93 [0.30, 2.96]
10 SAE: Alopecia (G2)	2		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
10.1 TBD/PLD vs PLD	1	663	Risk Ratio (M‐H, Random, 95% CI)	0.90 [0.60, 1.34]
10.2 CAN/PLD vs PLD	1	122	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
11 SAE: Abdominal pain (G3/4)	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
11.1 EC145/PLD vs PLD	1	157	Risk Ratio (M‐H, Random, 95% CI)	1.87 [0.41, 8.48]
12 SAE: Neuropathy (G3/4)	2		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
12.1 TBD/PLD vs PLD	1	663	Risk Ratio (M‐H, Random, 95% CI)	1.40 [0.85, 2.31]
12.2 EC145/PLD vs PLD	1	157	Risk Ratio (M‐H, Random, 95% CI)	4.25 [0.23, 77.45]
13 SAE‐related death	2		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
13.1 TBD/PLD vs PLD	1	663	Risk Ratio (M‐H, Random, 95% CI)	2.48 [0.48, 12.68]
13.2 EC145/PLD vs PLD	1	157	Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
14 Dose reductions	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
14.1 CAN/PLD vs PLD	1	535	Risk Ratio (M‐H, Random, 95% CI)	1.07 [0.53, 2.14]
15 Dose delays	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
15.1 CAN/PLD vs PLD	1	535	Risk Ratio (M‐H, Random, 95% CI)	1.50 [1.00, 2.26]